A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. - Wikidata - wikimedia - TriplyDB

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.

http://www.wikidata.org/entity/Q50046798

about

Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.Tumor immunity and survival as a function of alternative neopeptides in human cancer.Current Strategies to Enhance Anti-Tumour Immunity.Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.Population-level distribution and putative immunogenicity of cancer neoepitopes.Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside.Next generation of immune checkpoint therapy in cancer: new developments and challenges.The perfect personalized cancer therapy: cancer vaccines against neoantigens.Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment.Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions.Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis

P2860

Q49432766-5D650962-E617-4CCA-9271-00E00ADEC139 Q50020805-27F4E071-5BB5-4C8D-9173-A4DF222EED8F Q52344613-6D6DA753-5DFD-4DB3-B151-B6C64CF9E2DD Q52587406-23DAAA6F-2CCB-459A-8DFD-50864A0DAC3D Q52589523-719D0154-A2CF-43DA-9FD2-A68EAEF66C17 Q52615294-7EFF1145-9C6B-43A6-BCD8-7718329CF5D9 Q52653710-12CA3FF5-5DAB-4E3C-9337-2CFFDF82840A Q55001351-DF4424EC-8D6E-4B88-8C01-E2F0FC2774BB Q55114350-E225F180-E024-4808-91F8-6DF0874D9B8A Q55240544-67AE58B6-9A5A-4122-92E6-41A2C7361F37 Q55287125-46856867-F0C4-4CF9-B188-505D96EE0218 Q56891212-EE340D3B-6354-43D9-BDED-327470C2470B Q56891609-CE4AE20A-B114-40CD-B4C5-E6038902CD97 Q57810732-C255CC98-1EAF-476E-8524-A80C8DCCA4C6 Q58736099-8D54CF88-294B-4AAC-89D5-D030C8F291BF

P2860

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.

http://www.wikidata.org/entity/Q50046798

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.

@en

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.

@nl

type

label

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.

@en

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.

@nl

prefLabel

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.

@en

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.

@nl

P1433

Q50046798-D44B9EEB-0582-4FDA-9C06-F4D4D5C15199

P1476

Q50046798-8B6E4AF5-B1EF-474F-A5CF-3D393590865F

P2093

Q50046798-0CE9106D-AE7A-4BA2-A449-2B887AED6B88

Q50046798-2A3A3B7A-89F7-4F3A-9361-79BC1609588D

Q50046798-370C9AE3-2301-4086-B629-88FC7A1FEB63

Q50046798-3834F9DC-D2DD-4094-8C4F-185156E72D1C

Q50046798-51DCE365-EE1E-4538-8791-9556E5FF0139

Q50046798-59C2CA03-6C27-4E48-B67B-C7D7177B71D6

Q50046798-7C3E281B-F112-4FD5-A615-DB3A1ED84683

Q50046798-83264144-CF66-4737-BDA5-2B88CE1B49C3

Q50046798-89B54738-0D11-4100-90E8-BE16C34E6BBC

Q50046798-CC9C34C4-12E1-48F2-9329-7F639460ED76

P2860

Q50046798-09E9B7BF-BB94-46CD-83C8-DFEB98745FD3

Q50046798-14568F38-4625-4E84-8CFC-2F3BC2A4818C

Q50046798-1729FD44-FC25-4114-8A33-4F42924E00CF

Q50046798-1A1BAF09-AEA0-446D-B159-88BBDD8DA7BD

Q50046798-1BA0797E-C846-435E-ADA0-B1C078011CDC

Q50046798-1DE3C784-1637-4253-BF09-1E858A7367CA

Q50046798-23103434-615D-44E1-AA42-5214628EF053

Q50046798-30E0BB87-5B2A-4D1C-BDC1-26CD42808B7F

Q50046798-35F0EC60-BB80-4DF2-A68C-B7A407448491

Q50046798-393048AE-AEE3-446B-B22A-706C9A1F4310

P2888

Q50046798-B553825C-8116-4BE4-A9E8-266005D125D6

P304

Q50046798-4249AA25-5672-49D6-9464-7D6A9CF244F0

P31

Q50046798-F0D56D7E-905A-4FAA-AC34-C6717CB960D3

P356

Q50046798-2F7156B2-39BE-4DFE-8018-D5B448602364

P407

Q50046798-E7CF1AE9-57D1-497C-BA07-C423346D8D0E

P433

Q50046798-466A7A86-4A3F-408C-A035-2296A3CB95C6

P478

Q50046798-50A627A5-75C1-47F5-970A-2B088F609653

P50

Q50046798-6AB77DC6-9726-42DA-A820-0BE14AD4F2B0

P577

Q50046798-0C3D81BE-B982-46BE-9A7A-864BF5038435

P6179

Q50046798-80A70989-A182-4996-A068-373DBEC46B93

P698

Q50046798-FC8361F0-1C3B-4AE0-9E6C-58D97835C137

P921

Q50046798-A54B72BB-F925-4868-B27D-546FCC675F6F

P932

Q50046798-11B07784-DF9D-4574-8CFF-517EE095685F

P356

P1433

P1476

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy

@en

P2093

Alexander Solovyov

http://www.w3.org/2001/XMLSchema#string

Arnold J Levine

http://www.w3.org/2001/XMLSchema#string

Benjamin D Greenbaum

http://www.w3.org/2001/XMLSchema#string

Jedd D Wolchok

http://www.w3.org/2001/XMLSchema#string

Marta Łuksza

http://www.w3.org/2001/XMLSchema#string

Matthew D Hellmann

http://www.w3.org/2001/XMLSchema#string

Naiyer A Rizvi

http://www.w3.org/2001/XMLSchema#string

Taha Merghoub

http://www.w3.org/2001/XMLSchema#string

Timothy A Chan

http://www.w3.org/2001/XMLSchema#string

Vinod P Balachandran

http://www.w3.org/2001/XMLSchema#string

P2860

Amino acid substitution matrices from protein blocks

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Deconstructing the Peptide-MHC Specificity of T Cell Recognition

Tumor neoantigens: building a framework for personalized cancer immunotherapy

Immune checkpoint blockade: a common denominator approach to cancer therapy

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Genetic basis for clinical response to CTLA-4 blockade in melanoma

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Neoantigens in cancer immunotherapy.

P2888

P304

517-520

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE24473

http://www.w3.org/2001/XMLSchema#string

P407

P433

7681

http://www.w3.org/2001/XMLSchema#string

P478

551

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092574574

http://www.w3.org/2001/XMLSchema#string

P698

29132144

http://www.w3.org/2001/XMLSchema#string

P921

P932

6137806

http://www.w3.org/2001/XMLSchema#string